Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Status:
Completed
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with
Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate
insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting glucose
levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that after 30
weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C (A1C) relative
to withdrawing sitagliptin.